nimacimab glp-1 news Skye Bioscience, Inc. (SKYE) Securities Class Action Lawsuit Update [December 10, 2025] Skye Bioscience's Nimacimab: A Transformative

Read the full article in Journal of Substance Abuse Treatment: Learn more about the implementation research in addiction: #ImplementationScience #AddictionResearch #EvidenceBased #NIH #NIDA #PublicHealth #ResearchToPractice To view or add a comment, sign in GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain

Neff LM, Kushner RF

F.ShenL

2022;23(11):5938 Forman HJ, Zhang H

In recent years, it has attracted great attention due to its potential in the treatment of various pathological diseases, including skin and cosmetic diseases (Hwang et al., 2017)